Background Acne vulgaris is a common chronic inflammatory skin disease involving pilosebaceous units. Both innate and adaptive immunity, especially the T helper 17 pathway, may contribute to the inflammatory response in acne. Objectives We aimed at evaluation of serum interleukin‐17 (IL‐17) level in patients with acne vulgaris in order to assess its role in disease pathogenesis and its clinical significance. Methods Serum IL‐17 level was measured by an ELISA technique in 80 acne vulgaris patients and 80 apparently healthy controls. Results Serum IL‐17 level was significantly higher in acne vulgaris patients than control group (P < 0.001). Moreover, it was increasing significantly with the increase in disease severity and in patients with scarring lesions (P < 0.001 each). Conclusions Serum IL‐17 is not only a biomarker of disease pathogenesis but also it could be a potential prognostic predictor for severity and scarring in acne vulgaris.

Background: Non-alcoholic fatty pancreatic disease (NAFPD) or fatty pancreas emerged as health problem parallel to obesity. NAFPD can lead to diabetes mellitus, chronic pancreatitis and lastly pancreatic cancer. Extra pancreatic complications to cardio-vascular system are reported to more than expected. Aim: To investigate the association between carotid and aortic intima-media thickness and non-alcoholic fatty pancreas disease. Method: eighty-eight patients divided into 4 groups , group (1)diabetics with normal Body Mass Index( BMI) , group (2) diabetics with BMI over 25 kg/m 2 , group(3) non-diabetics with normal BMI , group (4) non diabetics with BMI over 25kg/m 2 . All routine investigations necessary done including, Complete Blood Count (CBC), fasting blood sugar , HbA1c%, liver profile including (ALT , AST , GGT , ALP , serum bilirubin and serum albumin) , lipid profile including (cholesterol , triglycerides , HDL , and LDL) , serum insulin level . Abdominal ultrasound for diagnosis, grading of fatty pancreas and measure Cartotid Intima Media Thickness( CIMT) and Aortic Intima Media Thickness (AIMT). Result: AIMT was as follow (0.96-+0.26) for healthy normal ,(1.38-+0.20)for non DM -obese,(1.24-+0.18)DM , non-obese and (1.52-+0.37) for DM -obese patients respectively with p value between the groups =<0.001.CIMT was as follow (0.58-+0.18) for healthy normal ,(0.73-+0.18)for non DM -obese,(0.86-+0.20)DM , non-obese and (1.01-+0.25) for DM -obese patients respectively with p value between the groups =<0.001 Conclusion: Both AIMT and CIMT manifested in the patients groups even the normal healthy subjects which is

Background: Non-alcoholic fatty pancreatic disease (NAFPD) encompasses a broad range of conditions ranging from pancreatic fat accumulation (fatty pancreas, pancreatic steatosis) to pancreatic inflammation (non-alcoholic steatopancreatitis) and probable pancreatic fibrosis. FABP1 is a 14-kDa protein that is involved in cytoplasmic fatty acid metabolism. Additionally, FABP1 enhances the transport, storage, and use of fatty acids and their acyl-CoA derivatives and may protect against lipotoxicity by accelerating their oxidation or incorporation into TGs and binding other cytotoxic fatty acids. Aim: This study aimed to assess the diagnostic role of FABP1 in patients with a non-alcoholic fatty pancreatic disease with and without Diabetes Mellitus.Method: This was a cross-sectional study which was carried on 88 subjects who were evaluated through complete history, clinical and biochemical assessment, and abdominal ultrasound. FABP1 was determined using ELISA kits. Result: The studied patients showed a mean age of 44.08±12.41 years and a BMI mean of 29.73 ±8.15 kg/m2. 72% of patients were males. FABP1 levels were significantly elevated among diabetic patients with BMI >25 (P=0.02). There was a statistically significant relation between FABP1 expression with high grades of fatty pancreas among non-diabetic subjects with BMI over 25 (P=0.013). At cut-off 0.758, the sensitivity of FABP1 in the prediction of the fatty pancreas was (68.2%), specificity (45.5%), and area under the curve was 0.618 in diabetics and non-diabetics with normal BMI. Conclusion: We suggest that FABP may be a good marker for the diagnosis of NAFPD.

Bladder disease is the tenth most normal malignant growth around the world. The analysis and follow-up of patients require exorbitant obtrusive strategies and because of these costs, bladder disease keeps on being one of the costly malignancies. Early determination is pivotal in bladder disease for what it's worth in different tumors; in this way, non-intrusive biomarkers for early conclusion are vital. The point of the investigation was to analyze urinary insulin-like development factor 2 (IGF-2) levels in persistent pee tests and decide the capability of IGF-2 as a marker for the presence of urothelial carcinoma of the bladder (UCB). Techniques: 50 patients with bladder disease and 20 solid controls. Quantitative constant converse tran¬scription polymerase chain response (qRT-PCR) was led to quantify the IGF-2 articulation levels in pee of patients with bladder malignant growth and sound con¬trols. Results: patients with UCB have essentially raised degrees of urinary IGF-2.

The role of microRNAs (miRNA) in many diseases, including chronic hepatitis, represents an interesting research field. The current work aimed to study the effect of combination therapy (pegylated interferon alpha-2b plus ribavirin) on microRNA-128 (miR-128) and microRNA-296 (miR-296-5p) expression in patients with chronic hepatitis C. Also, we aimed to investigate the potential value of both types of microRNAs in differentiation between responders and nonresponders either in the pre-treatment or post-treatment groups. Sixteen patients with chronic hepatitis C were compared to 10 healthy, age and sex matched controls. Venous blood samples were withdrawn before initiation of combination therapy and 12 weeks later and qPCR was used for gene expression assays. Comparison of pre-treatment group to the control group showed significant miR-128 down-regulation, while miR-296-5p showed a non-significant downregulation. Regarding post-treatment group, there was non-significant upregulation of miR-128, while miR-296-5p was significantly downregulated compared to either pre-treatment group or the control group. Comparative studies of miR-128 and miR-296-5p in responders versus nonresponders showed non-significant fold change either in the pre-or post-treatment groups. It could be concluded that chronic hepatitis C as well as the combination therapy modulate miR-128/296 expression. Until now, miRNAs studied were not useful indicators to differentiate between responders and non-responders to combination therapy either in pre-or post-treatment group. Keywords  miRNA  Chronic HCV  Combination therapy Bull. of Egyp. Soc. Physiol. Sci.